Abstract | OBJECTIVES: STUDY DESIGN: One group of 11 children with PWS <2 years before and during 30-month GH therapy (GH group) was compared with 6 infants administered only coenzyme Q(10) for 1 year (Q10 group). LM adjusted for height (LM(Ht)) and relative fat mass (%FM(Age)) standard deviation scores (SDS) were calculated from data of 95 healthy children. RESULTS: Initially, LM(Ht) of all patients was below the normal average. LM(Ht) decreased by -0.46 +/- 0.3 SD (P=.03) per year in the Q10 group but rose by 0.25 +/- 0.3 SD (P=.02) per year during GH therapy, normalizing after 30 months (-0.70 +/- 1.0 SD). Despite low to normal weight for height (WfH), %FM(Age) was above the normal average (GH group, 31.0% +/- 4.5%, Q10 group, 32.4% +/- 9.5%). In the Q10 infants, %FM(Age) increased by 0.71 +/- 0.7 SD per year, whereas in the GH group, %FM(Age) remained more stable up to 30 months. CONCLUSIONS: Diminished LM(Ht) found in infants with PWS further declines during the early years. Early institution of GH therapy lifts LM(Ht) into the normal range and delays fat tissue accumulation.
|
Authors | Urs Eiholzer, Dagmar L'allemand, Michael Schlumpf, Valentin Rousson, Theo Gasser, Christoph Fusch |
Journal | The Journal of pediatrics
(J Pediatr)
Vol. 144
Issue 6
Pg. 753-8
(Jun 2004)
ISSN: 0022-3476 [Print] United States |
PMID | 15192622
(Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Recombinant Proteins
- Human Growth Hormone
- Ubiquinone
|
Topics |
- Body Composition
(drug effects)
- Female
- Human Growth Hormone
(pharmacology, therapeutic use)
- Humans
- Infant
- Male
- Obesity
(prevention & control)
- Prader-Willi Syndrome
(drug therapy)
- Recombinant Proteins
- Statistics, Nonparametric
- Ubiquinone
(pharmacology, therapeutic use)
|